|
|
Post by agedhippie on May 29, 2024 21:54:44 GMT -5
The two companies also agreed that Pulmatrix will transfer its Bedford, Mass. R&D facility to MannKind, along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction. Were they going bankrupt? Pulmatrix Inc Follow NASDAQ: PULM Market cap of 7m. More like trying to avoid going bankrupt. PULM have offloaded their lease and operations costs to lower their burn rate while they do their phase 2 trial, and MNKD has got an R&D facility that they can consolidate into. I would be shocked if either side ever exercised their rights to the other sides technology - that's fluff. |
|
|
|
Post by cjm18 on May 29, 2024 23:43:17 GMT -5
The two companies also agreed that Pulmatrix will transfer its Bedford, Mass. R&D facility to MannKind, along with all leasehold improvements, laboratory equipment and other related personal property used in the laboratory in non-cash transaction. Were they going bankrupt? Pulmatrix Inc Follow NASDAQ: PULM Market cap of 7m. More like trying to avoid going bankrupt. PULM have offloaded their lease and operations costs to lower their burn rate while they do their phase 2 trial, and MNKD has got an R&D facility that they can consolidate into. I would be shocked if either side ever exercised their rights to the other sides technology - that's fluff. Hmm why did mannkind want the Boston facility. |
|
|
|
Post by letitride on May 30, 2024 2:40:35 GMT -5
Given Mikes recent comments on MNKD-501 and clofazimine I am leaning toward the technology may be what he was after and the facility was a bonus. Why take on some of PULM staff if the building was the goal?
|
|
|
|
Post by bthomas55ep on May 30, 2024 5:15:14 GMT -5
Given Mikes recent comments on MNKD-501 and clofazimine I am leaning toward the technology may be what he was after and the facility was a bonus. Why take on some of PULM staff if the building was the goal? Doesn't MNKD just acquire Pulmatrix and the iSphere technology if the phase 2 migraine studies are promising and they begin running low on cash again (before their next capital raise) and fold this all back together ultimately adding DHE to the MNKD portfolio? I found it interesting on the pipeline page on the Pulmatrix Web site for the PUR3100 trials, they report the IND has been accepted for the Phase 2 trials, but in the side note on the table, it also says "pursuing partnership". Let Pulmatrix burn the rest of their cash proving out the drug and then mnkd becomes their white knight when it heads to phase 3? Don't really know anything, just rambling here. GLTA |
|
|
|
Post by sayhey24 on May 30, 2024 7:00:40 GMT -5
Al didn't invent Technosphere. Sol Steiner did. I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse? I guess we all kind of figured they had issues putting clofazimine on TS so maybe iSpherse helps? Who knows maybe iSpherse would work better with Saxenda but Al Mann had some pretty great results putting native GLP1 on Technosphere. I am not sure I like paying for more R&D when we need to do the afrezza GLP1 trial and we need to do the Saxenda DPI trails. I also thought we had already put something on TS for migraines and had some good initial results but I don't remember what happened here. I just hope we are not signing up for another boondoggle. >>I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse?<< No one said DHE does not work with iSPHERE. My interpretation is that PULM needed a better inhaler and wants to use the Cricket. My interpretation is their inhalation system (inhaler plus iSpherse) are not working so well for DHE. Cricket was engineered to deliver Technosphere particles - not iSpherse particles. Would it work with iSpherse with no modifications - maybe but probably needs some modifications which would then make it a new inhaler not Cricket. At the same time this company is running out of money and by off loading the R&D staff and facilities they can keep the doors open maybe another year while hoping for a Hail Mary. At the same time maybe iSphere helps MNKD-101 but based on past performance I think Mike saw another opportunity to do some dumpster diving instead of focusing on the afrezza and GLP1 studies he should be doing. |
|
|
|
Post by Thundersnow on May 30, 2024 8:24:31 GMT -5
Given Mikes recent comments on MNKD-501 and clofazimine I am leaning toward the technology may be what he was after and the facility was a bonus. Why take on some of PULM staff if the building was the goal? Doesn't MNKD just acquire Pulmatrix and the iSphere technology if the phase 2 migraine studies are promising and they begin running low on cash again (before their next capital raise) and fold this all back together ultimately adding DHE to the MNKD portfolio? I found it interesting on the pipeline page on the Pulmatrix Web site for the PUR3100 trials, they report the IND has been accepted for the Phase 2 trials, but in the side note on the table, it also says "pursuing partnership". Let Pulmatrix burn the rest of their cash proving out the drug and then mnkd becomes their white knight when it heads to phase 3? Don't really know anything, just rambling here. GLTA Maybe PULM is looking to partner their 3100 Migrane drug. They do not have the resources for a Phase 3 trial. Also could be the reason why MNKD didn't buy the company. With a $7M MC it wouldn't take much to buy them....maybe $10M w/ incentives? Migrane is not in MNKDs Core strategy but could be a new division? |
|
|
|
Post by Thundersnow on May 30, 2024 8:27:53 GMT -5
>>I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse?<< No one said DHE does not work with iSPHERE. My interpretation is that PULM needed a better inhaler and wants to use the Cricket. My interpretation is their inhalation system (inhaler plus iSpherse) are not working so well for DHE. Cricket was engineered to deliver Technosphere particles - not iSpherse particles. Would it work with iSpherse with no modifications - maybe but probably needs some modifications which would then make it a new inhaler not Cricket. At the same time this company is running out of money and by off loading the R&D staff and facilities they can keep the doors open maybe another year while hoping for a Hail Mary. At the same time maybe iSphere helps MNKD-101 but based on past performance I think Mike saw another opportunity to do some dumpster diving instead of focusing on the afrezza and GLP1 studies he should be doing. You will not give up on a TS GLP-1 (LOL). Al Mann talked about GLP-1 and could have pursued it. He didn't and we all know Al was a brilliant man. If Mike thought it was a viable opportunity he would have gone down that road. He hasn't and probably wont. End of Story. |
|
|
|
Post by casualinvestor on May 30, 2024 8:32:31 GMT -5
Saving themselves the cost of developing an inhaler sounds like a good idea for a company low on cash. The cricket is perfect for a reactive, not-taken-often medication like migraine relief.
In return for allowing use of the cricket and picking up some lease payments, Mannkind gets access to another dry powder inhalation system! One with a different profile than Technophere, but that looks like it will work with the high resistance inhaler Mannkind already has. I have not done my research on iSphere, but this sounds like a good deal for both companies.
Unfortunately, while inhaled DHE looks to be tolerated far better than IV DHE:
They also look to only have 1 year of cash left, or less.
|
|
|
|
Post by sayhey24 on May 30, 2024 8:46:20 GMT -5
My interpretation is their inhalation system (inhaler plus iSpherse) are not working so well for DHE. Cricket was engineered to deliver Technosphere particles - not iSpherse particles. Would it work with iSpherse with no modifications - maybe but probably needs some modifications which would then make it a new inhaler not Cricket. At the same time this company is running out of money and by off loading the R&D staff and facilities they can keep the doors open maybe another year while hoping for a Hail Mary. At the same time maybe iSphere helps MNKD-101 but based on past performance I think Mike saw another opportunity to do some dumpster diving instead of focusing on the afrezza and GLP1 studies he should be doing. You will not give up on a TS GLP-1 (LOL). Al Mann talked about GLP-1 and could have pursued it. He didn't and we all know Al was a brilliant man. If Mike thought it was viable opportunity he was have gone down that road. He hasn't and probably wont. End of Story. Al perused it and was very excited about it. However, as Al said there are 3 things you need to grow a business; money; money; and MORE Money. He had to set priorities and afrezza was #1. While thats the end of that story we are opening another. Iconovo thinks its a pretty great idea. I have made them aware of Mannkind's work 15years ago and I think they may have a winner. We will see. Look - I tried with MNKD and I will continue to be a broken record but it is what it is at this time. Mike decided to buy V-Go and now announced something with PLUM which has plummeted our pps. I have not yet seen any announcement on gestational diabetes so I guess Mike is still talking on this. I have also not seen any movement on the afrezza/glp1 study for T2s. I did however see how we can now use iSperse for insulin. I guess this is to replace technosphere but I have yet to figure that out but I am sure Mike has another plan. |
|
|
|
Post by hellodolly on May 30, 2024 8:52:21 GMT -5
>>I am not clear what this deal is about. It seems iSpherse does not work so well with their DHE treatment for acute migraine but Technosphere might and it seems that clofazimine doesn't work so well with Technosphere but may work better with iSpherse?<< No one said DHE does not work with iSPHERE. My interpretation is that PULM needed a better inhaler and wants to use the Cricket. My interpretation is their inhalation system (inhaler plus iSpherse) are not working so well for DHE. Cricket was engineered to deliver Technosphere particles - not iSpherse particles. Would it work with iSpherse with no modifications - maybe but probably needs some modifications which would then make it a new inhaler not Cricket. At the same time this company is running out of money and by off loading the R&D staff and facilities they can keep the doors open maybe another year while hoping for a Hail Mary. At the same time maybe iSphere helps MNKD-101 but based on past performance I think Mike saw another opportunity to do some dumpster diving instead of focusing on the afrezza and GLP1 studies he should be doing. I suspect PULM fits the definition of "that" sort of company Mike mentioned at JPM which MNKD would be willing to look at if it were "too good to pass up" and a fire sale sort of scenario? I suspect any inhaled dry powder formulations would fit nicely in the overall picture of MNKDs portfolio of drugs as well as two FDA approved inhaled delivery systems. I think this fits much better than V-Go. EDIT" As to the GLP-1 story, now we have two types of inhalers. Could another XYZ company, not on the radar, be exploring the GLP-1 option? Does MNKD have a better position of strength to bargain for that GLP-s deal or partnership with two platforms and two delivery devices? |
|
|
|
Post by Thundersnow on May 30, 2024 9:26:29 GMT -5
You will not give up on a TS GLP-1 (LOL). Al Mann talked about GLP-1 and could have pursued it. He didn't and we all know Al was a brilliant man. If Mike thought it was viable opportunity he was have gone down that road. He hasn't and probably wont. End of Story. Al perused it and was very excited about it. However, as Al said there are 3 things you need to grow a business; money; money; and MORE Money. He had to set priorities and afrezza was #1. While thats the end of that story we are opening another. Iconovo thinks its a pretty great idea. I have made them aware of Mannkind's work 15years ago and I think they may have a winner. We will see. Look - I tried with MNKD and I will continue to be a broken record but it is what it is at this time. Mike decided to buy V-Go and now announced something with PLUM which has plummeted our pps. I have not yet seen any announcement on gestational diabetes so I guess Mike is still talking on this. I have also not seen any movement on the afrezza/glp1 study for T2s. I did however see how we can now use iSperse for insulin. I guess this is to replace technosphere but I have yet to figure that out but I am sure Mike has another plan. I remember Al saying a TS GLP-1 works too fast and is not worth developing. |
|
|
|
Post by Clement on May 30, 2024 10:29:24 GMT -5
My guess is that PULM tested Cricket with iSperse particles prior to the recent deal. Who knows - but that would have been a wise move.
|
|
|
|
Post by stockwhisperer on May 30, 2024 10:40:18 GMT -5
Well, I do not agree that this deal plummeted the sp. In general, I don’t think the sp has ‘plummeted’ at all. The sp goes up & down - nothing goes up every day. Actually, I think it’s holding up fairly well considering the overall market conditions yesterday and today.
|
|
|
|
Post by mango on May 30, 2024 10:59:45 GMT -5
You will not give up on a TS GLP-1 (LOL). Al Mann talked about GLP-1 and could have pursued it. He didn't and we all know Al was a brilliant man. If Mike thought it was viable opportunity he was have gone down that road. He hasn't and probably wont. End of Story. Al perused it and was very excited about it. However, as Al said there are 3 things you need to grow a business; money; money; and MORE Money. He had to set priorities and afrezza was #1. While thats the end of that story we are opening another. Iconovo thinks its a pretty great idea. I have made them aware of Mannkind's work 15years ago and I think they may have a winner. We will see. Look - I tried with MNKD and I will continue to be a broken record but it is what it is at this time. Mike decided to buy V-Go and now announced something with PLUM which has plummeted our pps. I have not yet seen any announcement on gestational diabetes so I guess Mike is still talking on this. I have also not seen any movement on the afrezza/glp1 study for T2s. I did however see how we can now use iSperse for insulin. I guess this is to replace technosphere but I have yet to figure that out but I am sure Mike has another plan. They have already tested the iSperse dry powder with insulin and apparently had good results. The iSperse utilizes cationic salt formulations. The iSperse is just a proprietary dry powder formulations just like our FDKP formulations are. They load molecules onto it like we couple molecules onto FDKP. It can be used in various modalities, and works well with high resistance inhalers, which is exactly what MannKind has. Further, iSperse can be used for formulating drug combinations, I’m not sure how feasible that is with Technosphere. It also has a strong safety profile considering its formulations are comprised of GRAS salts. www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2012.185.1_MeetingAbstracts.A2761 |
|
|
|
Post by sayhey24 on May 30, 2024 11:16:36 GMT -5
Al perused it and was very excited about it. However, as Al said there are 3 things you need to grow a business; money; money; and MORE Money. He had to set priorities and afrezza was #1. While thats the end of that story we are opening another. Iconovo thinks its a pretty great idea. I have made them aware of Mannkind's work 15years ago and I think they may have a winner. We will see. Look - I tried with MNKD and I will continue to be a broken record but it is what it is at this time. Mike decided to buy V-Go and now announced something with PLUM which has plummeted our pps. I have not yet seen any announcement on gestational diabetes so I guess Mike is still talking on this. I have also not seen any movement on the afrezza/glp1 study for T2s. I did however see how we can now use iSperse for insulin. I guess this is to replace technosphere but I have yet to figure that out but I am sure Mike has another plan. I remember Al saying a TS GLP-1 works too fast and is not worth developing. Al was saying NATIVE GLP1 was not a viable drug because it worked too fast. We are not talking about native GLP1. We are talking about an analog like Saxenda which will be coming off patent soon. We should be able to quickly do a pilot and then go right to P2 since both TS and Saxenda are approved. All I am talking about is a pilot and lets see if it works. When I first brought this up Mike told me I was wrong about the GLP1 work. Then he found it and submitted the patent. I think $5M on the pilot is money better spend than any time with PLUM. First we paid the bill for the V-Go reps and then finally let them go. Now we are paying for another staff, who is foing God knows what. |
|
